Active Ingredient History
Anastrozole (marketed under the trade name Arimidex by AstraZeneca) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Aging (Phase 1)
Anovulation (Phase 2)
Arthralgia (Phase 4)
Bone Density (Phase 3)
Breast Density (Phase 1)
Breast Diseases (Phase 1/Phase 2)
Breast Neoplasms, Male (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Depression (Phase 2)
Diabetes Mellitus (Phase 2)
Dysmenorrhea (Phase 4)
Endometrial Neoplasms (Phase 2)
Endometriosis (Phase 4)
Epilepsy (Phase 2)
Erectile Dysfunction (Phase 2)
Eunuchism (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibrous Dysplasia, Polyostotic (Phase 2)
Growth and Development (Phase 4)
Gynecomastia (Phase 3)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hormones (Phase 3)
Hypertension (Early Phase 1)
Hypogonadism (Phase 4)
Hypopituitarism (Phase 2/Phase 3)
Iron Deficiencies (Phase 2)
Klinefelter Syndrome (Phase 3)
Mastectomy (Phase 2)
Menstruation Disturbances (Phase 2)
Metabolic Syndrome (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms ()
Obesity (Phase 4)
Obesity, Morbid (Phase 4)
Oligospermia (Phase 3)
Osteoporosis (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Postmenopause (Phase 4)
Progression-Free Survival (Phase 3)
Prostatic Neoplasms (Phase 2)
Prostheses and Implants (Phase 4)
Puberty, Precocious (Phase 2)
Pulmonary Arterial Hypertension (Phase 2)
Quality of Life (Phase 3)
Recurrence (Phase 2)
Safety (Phase 1)
Sarcoma (Phase 2)
Sarcopenia (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Uterine Diseases (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue